OPTIMIZING ADHERENCE FOR MATERNAL MULTIPLE MICRONUTRIENT SUPPLEMENTATION (MMS) IN NIGERIA

Introduction of MMS through antenatal care in Bauchi State, Nigeria:

Training for healthcare workers

JULY 2024







Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 1. Setting the Tone

✓ Registration

- ✓ Opening prayer and remarks
- ✓ Pre-test assessment
- ✓ Establishment of training rules



Module 1. Setting the Tone Establishment of training rules



What kind of rules would you like to set in place for the training?

Since these rules have been established through consensus, it is your responsibility to kindly follow them.



Module 1. Setting the Tone Background to MMS Introduction

- Antenatal care (ANC) has been recognized as a strategic platform to deliver services, promote health and prevent diseases.
- World Health Organization (WHO, 2020) recommended administering MMS instead of IFAS during pregnancy.
 - $_{\odot}$ Upcoming Modules will provide further details regarding MMS and IFAS.
- The Government of Nigeria through the Federal Ministry of Health (FMoH) expressed interest in transitioning from IFAS to MMS and requested more implementation evidence in the Nigerian context.



Module 1. Setting the Tone Background to MMS Introduction (cont'd)

- Building on ongoing collaborations between the Government of Nigeria and Nutrition International, this project aims to:
 - $_{\odot}$ Understand the realities of introducing MMS
 - $_{\odot}$ Explore how to increase pregnant women's adherence to MMS
- During the project's implementation period:
 - \circ All public ANC services in the three focal LGAs in Bauchi State will be providing MMS instead of IFAS.
- To support this, a 'standard introduction package' is provided, which includes this training and project-specific materials and tools.



Module 1. Setting the Tone Overview of the Training

Therefore, this training is part of a wider project that aims to support the introduction of MMS through ANC.

It is designed to:

- Enhance the healthcare workers' understanding of MMS
- Explore the considerations of MMS inclusion in routine ANC
- Provide instructions on the utilization of tools and processes developed for MMS implementation



Module 1. Setting the Tone Overview of the Training (cont'd)



Do you have any knowledge or experience with MMS you would like to share with us?

Please write down any insights or experiences you have on a sticky note and place it on the board (parking lot).



Module 1. Setting the Tone Overview of the Training (cont'd)

- As part of this training program, you will find in front of you essential resources needed for the provision of MMS, which include:
 - MMS Factsheet
 - MMS Standard Operating Procedures (SOPs)
 - Monitoring Form 1
 - Monitoring Form 2
- These resources will be thoroughly explained throughout the training.



- Iron Folic Acid Supplement (IFAS): A prenatal supplement that contains 30-60mg of iron and 400mcg of folic acid.
- **Multiple Micronutrient Supplementation (MMS):** A prenatal micronutrient supplement which contains 15 vitamins and minerals, including iron and folic acid, designed specifically for pregnant women to prevent anaemia and reduce the risk of their baby being born too small or too early.
- Adherence (related to MMS): WHO recommends MMS to be taken daily during pregnancy to prevent anaemia. For pregnant women to receive the most health benefits from the MMS tablets, high adherence throughout pregnancy is required.
 - \rightarrow Adherence is the extent to which a pregnant woman takes MMS daily.



Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 2. Nutrition During Pregnancy Increased Nutritional Needs of Pregnant Women

During pregnancy, nutritional needs are increased to:

- Meet physiological requirements
- Sustain fetal growth and development
- Protect the health of the mother during pregnancy and prepare for breastfeeding

Trimester	Estimated Energy Requirements (Cal/day)	1 snack (e.g. 1 small bowl of fresh fruits; a handful
1 st trimester	-	of groundnuts)
2 nd trimester	+ 340	
3 rd trimester	+ 452	1 small meal (e.g. 1 small piece of meat pie; 2 small Moi Moi wraps)



Module 2. Nutrition During Pregnancy Increased Nutritional Needs of Pregnant Women (cont'd)

Recommended Dietary Allowance (RDA) of selected micronutrients

	Non-pregnant		Pregnant	
RDA *	Adolescent girls (14-18 years)	Women (19-50 years)	Adolescent girls (14-18 years)	Women (19-50 years)
Iron (mg/day)	15	18	27	27
Folate (µg/day)	400	400	600	600
Vitamin A (µg RAE/day) **	700	700	750	770
Vitamin D (µg/day)	5	5	5	5
Vitamin E (mg/day)	15	15	15	15
Vitamin C (mg/day)	65	75	80	85
Vitamin B6 (mg/day)	1.2	1.3	1.9	1.9
Vitamin B12 (µg/day)	2.4	2.4	2.6	2.6
Zinc (mg/day)	9	8	12	11
Vitamin B1 (mg/day)	1.0	1.1	1.4	1.4
Vitamin B2 (mg/day)	1.0	1.1	1.4	1.4
Niacin (mg/day)	14	14	18	18
Copper (µg/day)	890	900	1000	1000
Selenium (µg/day)	55	55	60	60
lodine (μg/day)	150	150	220	220
Calcium (mg/day)	1300	1000	1300	1000

Non-pregnant vs. Pregnant: majority of micronutrient requirements are ↑

Daily iron requirement nearly doubles during pregnancy

* Bold font represents an Adequate Intake (AI)
** Tolerable Upper Intake Levels (ULs): 2800 µg
RAE/day for pregnant adolescent girls ages 14-18 years;
3000 µg RAE/day for pregnant women ages 19-50 years.

RAE: Retinol Activity Equivalent.





Module 2. Nutrition During Pregnancy Increased Nutritional Needs of Pregnant Women (cont'd)

Through food alone, it is difficult for pregnant women to meet their dietary needs

Poor nutrition status of the mother

Negative consequences on their own health and the health of their baby





Module 2. Nutrition During Pregnancy Increased Nutritional Needs of Pregnant Women (cont'd)

To achieve the required nutritional needs, pregnant women are advised to consume an adequate nutritious diet, in addition to daily adequate micronutrient supplementation.



Module 2. Nutrition During Pregnancy The Impact of Poor Nutrition on Pregnancy and Birth Outcomes

Poor nutrition during pregnancy \rightarrow micronutrient deficiencies \rightarrow negative impact on the health of the mother and her baby

Example:

Deficiencies in iron, folate, vitamin A and vitamin B12 can lead to anaemia – a serious global public health problem



Module 2. Nutrition During Pregnancy **The Impact of Poor Nutrition on Pregnancy and Birth Outcomes** (cont'd)



What are some negative health consequences of anaemia on the pregnant woman and birth outcomes?

- a. Maternal death
- b. Babies born too small
- c. Babies born too early
- d. Maternal tiredness
- e. All of the above


- Increased risk of maternal death
- Increased risk of poor pregnancy and birth outcomes,
- Preterm birth
- Low birth weight
- Maternal tiredness, weakness and/or dizziness



Module 2. Nutrition During Pregnancy High Burden of Pregnancy and Birth Outcomes in Nigeria

Neonatal mortality rate (2018)¹

- 39 deaths per 1000 live births in Nigeria
- 38 deaths per 1000 live births in Bauchi State



Sub-Saharan Africa reported the highest global neonatal mortality rate (2020): 27 deaths per 1000 live births ²

Nigeria and Bauchi State higher

Maternal mortality ratio (2018) 1

• 512 deaths per 100 000 live births in Nigeria



Global maternal mortality ratio (2020): 223 deaths per 100 000 live births ³

Twice as high in Nigeria

Module 2. Nutrition During Pregnancy High Burden of Pregnancy and Birth Outcomes in Nigeria

Low birth weight (2013) ¹

- 8.1% in Nigeria
- 9% in Bauchi State



Low birth weight (2018) ²

- 7.3% in Nigeria
- 12.1% in Bauchi State






Source: 1 NDHS (2013); 2 NDHS (2018); 3 WHO (2014)



Module 2. Nutrition During Pregnancy Anaemia among Women of Reproductive Age (WRA) (Year 2019)

 $\mathcal{\Gamma}$



Source: WHO 2023. The Global Health Observatory



Module 2. Nutrition During Pregnancy Preventing Anaemia and Other Deficiencies

To help prevent anaemia and decrease the risk of micronutrient deficiencies, pregnant women are recommended to consume:

(1) An adequate nutritious diet composed of a variety of foods, with emphasis on iron-rich foods (such as beef, poultry, and iron-fortified foods)

and

(2) Daily micronutrient supplementation that includes 30-60 mg of iron and 400 mcg of folic acid as recommended by the WHO ¹

• An example of such supplementation is MMS, which will be discussed in more detail later in this training.

Source: 1 WHO (2020)



Module 2. Nutrition During Pregnancy Adequate Nutritious Diet and Adequate Micronutrient Supplementation During Pregnancy (cont'd)



It is better for pregnant women to replace meals or foods with maternal dietary supplementation.





Micronutrient supplements are intended to **supplement the diet** and should **not** replace meals or foods.



Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



IFAS = Iron and Folic Acid Supplementation MMS = Multiple Micronutrient Supplementation

- Both are antenatal supplements
- IFAS includes 30-60mg of iron and 400mcg of folic acid (usually in two tablets in Nigeria)
- MMS provides 13-15 micronutrients, including iron and folic acid (all in one tablet).
- MMS is different from MNP (micronutrient powders, used for children).



Module 3. From IFAS to MMS IFAS versus MMS (cont'd)



Group Discussion:


Have you been providing dietary supplements to pregnant women as part of routine ANC in Nigeria and/or Bauchi State?

- If yes, which dietary supplement(s)? Please explain the reason for the provision of this specific supplement.
- If you are not providing dietary supplements, could you share why not?



Module 3. From IFAS to MMS IFAS versus MMS (cont'd)


Iron and Folic Acid Supplementation (IFAS)



Iron (30-60mg) Folic acid (400Ug)



Multiple Micronutrient Supplementation (MMS) *




*UNIMMAP formulation, which is is now part of the WHO's Essential Medicine List (2022) *MMS tablet may vary from picture presented above*



Module 3. From IFAS to MMS Evidence: effectiveness of MMS vs. IFAS

For maternal birth outcomes



Source: ¹ Keats et al, 2019; ² Smith et al, 2017 Image developed by Nutrition International 2020



Module 3. From IFAS to MMS WHO Guidelines (2016)



 \sum


Module 3. From IFAS to MMS WHO Guidelines (2016)

Nutritional Recommendation Update July 2020



Antenatal multiple micronutrient supplements that include iron and folic acid are recommended in the context of rigorous research. (Context-specific recommendation – research)









World Health Organization

WHO antenatal care recommendations for a positive pregnancy experience Nutritional interventions update: Multiple micronutrient supplements during pregnancy



Module 3. From IFAS to MMS National Guidelines



In 2021, following the WHO's updated guidelines, the Nigerian Federal Ministry of Health approved the use of MMS during pregnancy through its updated *National Guidelines for the Prevention and Control of Micronutrient Deficiencies in Nigeria*.



Module 3. From IFAS to MMS Implementation Research



NUTRITIO

 In response and support to the Government of Nigeria's request, Nutrition International commenced an implementation research* project on MMS

→ Started in July 2022

 Since December 2023, and for the duration of the project, MMS has been provided to eligible pregnant women (instead of IFAS) as part of routine preventative ANC in 3 selected LGAs in Bauchi State.

* To help Nigeria understand how to optimize adherence to MMS among pregnant women.

Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 4. Key Messages on the Provision of MMS Who gets MMS in this Implementation Research Project?

MMS is provided free of cost to all non-anaemic pregnant women accessing public ANC services.

o Preventative care

When the pregnant woman comes for her first ANC visit, she will be offered a bottle of MMS instead of IFAS.

Unopened bottle of 100 tablets



More information about MMS and the protocol to introduce it to pregnant women will be discussed in upcoming Modules.





Module 4. Key Messages on the Provision of MMS Who gets MMS in this Implementation Research Project?

- As part of this implementation research project, MMS is intended for pregnant women who are **newly enrolled** in public ANC services.
- MMS formula was designed to meet the specific needs of pregnancy.
 - It is not intended for use by other age groups or men.
 - ^o MMS is just for the pregnant woman and should not be shared with others.
- MMS is provided, **instead of IFAS**, to **non-anaemic pregnant women**.
- If anaemia is suspected, MMS is not given. The current recommended anaemia management protocol needs to be followed.



Module 4. Key Messages on the Provision of MMS Initiation, Dosage and Intake of MMS



As early in pregnancy as possible, the pregnant woman should begin taking one whole MMS tablet per day, every day, throughout her entire pregnancy.



- As soon as the woman knows she is pregnant, she should visit ANC where, as part of routine ANC services, she will get a bottle of MMS.
- She should begin taking one whole MMS tablet as early in pregnancy as possible, every day, throughout her entire pregnancy.
- If she has leftover MMS tablets, she can continue consuming the remainder on a daily basis after delivery.
- Details on the provision of the bottles of MMS will be presented in the SOPs.





MMS tablet should be swallowed with a glass of clean water.

- MMS should not be chewed nor crushed.
- MMS should not be taken with tea, coffee, nor with calcium or calcium rich foods (like milk) given their effect on decreasing the absorption of iron in the body.



If the pregnant woman forgot to take her MMS tablet:

- She should simply resume her regular regimen by consuming one tablet per day.
- It is important **not** to exceed the recommended daily dosage; i.e. She should not take two tablets the following day to make up for a missed dose.

If the pregnant woman stopped taking MMS for some reason and wishes to resume:

• She should continue by taking just one tablet per day.



Storage of the MMS bottle:

- MMS should be stored in its original bottle and kept tightly closed to prevent damage to the tablets.
- The MMS bottle should be stored away from direct sunlight, away from direct heat, in a dry and safe place, and out of reach of children.





Brief recap discussion:

- When is MMS recommended?
- When is MMS not recommended and why?




- It is important for pregnant women to take MMS daily to receive the most health benefits from the MMS tablets. This is referred to as **'adherence'**.
- Adherence is defined as the extent to which a patient follows the advice prescribed by the healthcare worker/practitioner.
 - In the case of MMS, adherence means taking the MMS tablet every day throughout the pregnancy.
- As healthcare workers, it is crucial to assess and encourage pregnant women's adherence to MMS during each ANC visit. Some sample questions include:
 - ^o Did you start taking your MMS?
 - Have you been able to take your MMS daily?
 - ^o Why do you think you have not been able to take your MMS daily?
 - Would you like to discuss how I can support you with overcoming these barriers?





Module 4. Key Messages on the Provision of MMS Adherence Gap



Module 4. Key Messages on the Provision of MMS Adherence Gap (cont'd)



Brief group discussion:


In your opinion/building on your experience, what might be barriers/challenges to MMS adherence among pregnant women in Bauchi State?



- A pregnant woman can take MMS if she has diabetes, high blood pressure, heart disease, malaria, or a history of miscarriage.
- MMS is **safe** and does not have major side effects.
- Pregnant women may experience some minor discomfort which is usually temporary until their body adjusts to the iron in the tablet.
 - Some of these minor discomforts include: constipation, upset stomach, mild headaches and/or nausea.
 - ^o This is typically less than what is experienced with IFAS (lower iron dosage).



Recap of Day 1



- Consequences of anaemia
- Increased micronutrient needs during pregnancy
- MMS vs IFAS
- From IFAS to MMS
- Key messages on the provision of MMS
- MMS Adherence



Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 5. MMS Factsheet Content Overview





Utilization at the health facility:

 Healthcare workers can use this MMS Factsheet as a reference when explaining to the pregnant woman about MMS.

Provision to the pregnant woman:

• When giving the pregnant woman her MMS bottle, healthcare workers should also provide the pregnant woman with a copy of the MMS Factsheet for her personal reference.

Note: A sample of this project's MMS Factsheet is available upon request.



Module 5. MMS Factsheet
Use of MMS Factsheet

Role playPractice using the MMS Factsheet.



Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 6. Standard Operating Procedures (SOPs) **Content Overview**

Nourish Life



NUTRITION

Module 6. Standard Operating Procedures (SOPs) Content Overview





- At each ANC visit, a set of recommended services are expected to be offered to pregnant women → Continue to follow these recommendations as per government protocols.
- In addition, as part of this implementation research project, follow the project's SOPs for guidance on the provision of MMS for preventative care.
- In the context of Nigeria, it is recommended for pregnant women to receive a minimum of 4-8 ANC visits. Ideally, the first ANC visit should occur as early in pregnancy as possible.
- For this implementation research project, only pregnant women newly enrolled in ANC will be eligible to receive MMS instead of IFAS.
- Screening for anaemia in pregnant women is crucial and should be done by following the existing local protocols.
- · Anaemia screening results should be recorded in the relevant existing documents.



If anaemia is suspected:

- The recommended anaemia management protocol should be followed depending on severity. MMS should not be started (or continued) at this point.
- MMS is intended for preventative care and should be started (or continued) if there is no anaemia (or if the anaemia has been managed/resolved).



If NO anaemia is suspected:

- MMS is provided to pregnant women in unopened bottles of 100 tablets each (~ three-months supply of MMS)
- 1st bottle of MMS: should be provided to her during her first ANC visit
- 2nd bottle of MMS: should be provided approximately three-months later (or once the woman has consumed the first 100 tablets).



- MMS is intended to be taken as a supplement to an adequate nutritious diet → Continue providing nutrition counselling
- At each ANC visit, it is important to address any adherence issues throughout counselling.
- During each ANC visit, pregnant women should be reminded:
 - To take their MMS daily
 - When they will need to come back for their next ANC visit
 - When they will be due for their 2nd bottle of MMS

Note: A sample of this project's SOPs is available upon request.




Module 6. Standard Operating Procedures (SOPs) Interpersonal Communication (IPC)

Exchange of verbal and non-verbal communication

Channel for the exchange of information, thoughts and feelings


Integral component in quality antenatal care

Fundamental in building trust and increasing satisfaction and adherence to their health plan, including taking MMS





Module 6. Standard Operating Procedures (SOPs) IPC Techniques



For building trust:

- Greeting the woman
- Inviting her to share her thoughts
- Providing encouragement
- Actively listening

For fostering interactive communication:

- Asking open-ended questions
- Seeking clarification
- Encouraging questions and share her concerns
- Asking her for her ideas and preferences
- Assessing her understanding of MMS and her action plans











Group discussion of different scenarios using the SOPs as a guide: <u>Profile card 1</u>:

A pregnant woman who presents at her first ANC visit and has not yet taken any IFAS or MMS.

Is she eligible for MMS (Yes/No)? Why?





Assess anaemia first. If no anaemia, then **eligible for MMS**.



Group discussion of different scenarios using the SOPs as a guide: <u>Profile card 2</u>:

A pregnant woman who presents at her first ANC visit during her first trimester, has been diagnosed with anaemia and has not yet taken any IFAS or MMS.

62

Is she eligible for MMS (Yes/No)? Why?





Group discussion of different scenarios using the SOPs as a guide: <u>Profile card 3</u>:

A pregnant woman who arrives late in her pregnancy (later in second or in third trimester) for her **first ANC visit** and has not yet taken any IFAS or MMS.

Is she eligible for MMS (Yes/No)? Why?





Assess anaemia first. If no anaemia, then **eligible for 1 bottle of MMS**.



Group discussion of different scenarios using the SOPs as a guide: <u>Profile card 4</u>:

A pregnant woman who arrives later in second trimester for a follow-up ANC visit and has completed her first bottle of MMS.

Is she eligible for MMS (Yes/No)? Why?





Assess anaemia first. If no anaemia, then **eligible for her second bottle of MMS**.



Group discussion of different scenarios using the SOPs as a guide: <u>Profile card 5</u>:

A pregnant woman who arrives for her follow-up ANC visit after her anaemia has been resolved.

Is she eligible for MMS (Yes/No)? Why?





Yes, she is eligible for MMS.

Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



- To collect, review and learn from data on a regular basis to better understand the program, its effectiveness, whether it is achieving the intended targets and identify areas for improvement in real-time.
- During the project design phase, a plan is established to structure the project's monitoring system and define what is collected, how, when and by whom.



- MMS is a new commodity and has not been included in the government routine monitoring systems.
- A complementary monitoring system will need to be established to:
 - Help capture information about MMS
 - Help track what commodities pregnant women receive, manage stocks and facilitate project course correction as needed
- **Project-specific Monitoring Form 1 and Form 2** were developed for this project to collect information pertinent to the pregnant woman and track MMS stock.
 - \circ They are presented in the next slides.



- During each ANC visit (even if the pregnant woman is not taking MMS), healthcare workers need to:
 - Fill out their existing ANC forms/records following their usual reporting protocol

AND

Complete their relevant project-specific forms



Module 7. Monitoring and reporting Monitoring Forms to be Completed

Every time a pregnant woman comes to her ANC visit (even if she is not taking MMS) you need to:



Fill out the **existing ANC forms/records** as per usual protocol (with slight modifications)

- Health Facility Daily Register
- Integrated Maternal and Child Health Booklet
- Health Facility Monthly Summary Form
- ANC card



Contact Nutrition International for Resources & Guidance


and

State & LGA officers

Complete your relevant project-specific form: **Monitoring Form 1**

State & LGA officers

Module 7. Monitoring and reporting Monitoring Forms to be Completed (cont'd)




State & LGA officers

Module 7. Monitoring and reporting Monitoring Forms to be Completed (cont'd)



Integrated Maternal and **Child Health Booklet**



- Complete as per local existing ٠ protocols, except for pregnant women who are receiving MMS.
- For MMS: •

In the section of 'Iron Folate Given' Prescription tablets'

 \rightarrow tick "No" and report the provision of MMS beside the dates

*

Health Facility Monthly Summary Form

			leatification								
		Painter P	Facility.			Moeth Your					
		LGA.	1 9/192			Public		Private			
		Same .					e of Belts				
		Facility						Г			
			lealth Facility Attendance	0-28 25d - 11 days miths	Male 12.59 5.9 mths 978	10-19 8-28 379 820 yrs days	29d - 12 - 58 11 withs miths	5 - 9 10 - 19 Ym ym 220 ym	Tutal		
		1	Gensent Attendance Out-patient Attendance								
		3	Patients addressed	6-28 29d - 11 days mills	Male 12-58 5-9 mills 7%	10 - 19 315 228 315 days	Fee 29d - 12 - 59 11 ouths miths	5-9 10-19 Yrs 20 220 yrs	Tetal		
V		4.0	opatient doctorgen				1 1 1				
.			Mortality (Deaths)	A 78 784 11	Mala 12-59 5-9 millo 379	58.19	Fe	5 - 4 10 - 19 Yrs yrs 230 yrs	Tatal		
		1	Desta series and interface of the series	8-28 29d - 10 days miles	mitte yrs	yrs 220 yrs day	ti miles miles	Yes yes 230 yes		•	
m	ary	1	Deaths among individuals (disaggregated by age) Maternal Mortality				10-19 515	≥20 yrs			
	ar y	6 10	Station of woman related to programs y (maternal deaths) Causes of deaths								
		7				cted labour Abortion		Anacetia HSV	Other		
			Confirmed neuratal deaths due ta:	Prematarity	-	Nonsatal Tetaren	Coregrade		Mer		
			Confirmed under 5 deaths due to:	Malaria		Pocumania	Mal	natrition (Hher		
			Maternal Health (Ante-Natal Care)	2					Total		
		10	Antenatal attendance by prognant war	nen	10-14 515	15-19 m 2	1-54 srs 35	- 49 yrs ≥ 50 srs			
		11	Antenatal attendance first visit		gestation age bet	are 20 weeks (GA < 20w	(c) gestation age 20	weeks or later (G.4, $\geq 10{\rm wks})$			
		12	Prognant warness that attended actenated cliese, for 4th visit		1						
		12.0	Prognant wamen that attended astenatal clinic for 8th visit								
			Pregnant wanten counselled on Fernale General Maritation (FGN Pregnant wanten counselled on Famila Plasming (FP)	0							
		16	Pregnant women counselled on Material Nutrition during ANC								
		17	ANC syphila test date: ANC syphila test passive								
		19	ANC syphilis case treated								
			ANC Hepates B test done ANC Hepates B test positive								
		22	ANC Hispatitis B case referred for treatment								
		24	ANC Hepstim C test done ANC Hepstitus C test positive								
		25	ANC Hoperitie C case referred for incatment Pergenerit weatern who received malaria infermitical preventive to								
		27	Prognant women who received malaria intermetion proceetive t	represent second days	e (IPT2)						
		-28	Pregnant women who received malaria intermittent preventive t	trainsent field dose (16135						_
29	Pregnant women w	ho n	eceived malaria intermitte	ent prev	entive	treatment	more th	nan third do	se (IP	T>=4)	
	Pregnant women w										
				a and E.	L.A.	d					-
31	Pregnant women w	no n	eceived Haematinics (Iro	n and Fo	one Ac	id supple	ments)				-
32	Pregnant women w	ith s	evere anaemia							*	_
33	Pregnant women w	ith p	proteinuria								
		44	Abertions		_	Induced		Spontaneous (nan-Induced	0		
		45	Wismen who received Post Abortion Care (PAC)						-		
		40	Mumon identical for complications of analy abortion Maternal Health (Post-Natal Care)							1	
			Maternal Health (Post-Natal Care)			Mot	hers	Newborns	-		
		47	Postnatal close viz			1 day days	4-7 days >7 days 1.	day days days w7 d	Total		
			Newborn Health (Outcome of pregnancy)		Male		<2.5kg	Female	Total	1	
			Line Baths	4	Skg	20.5%g	+2,54g	32.5kg		-	
			Live Baths by HIV positive women only			Maccrated	MSR	Fresh Still Births (FS)		-	
		50	Stall Barths								
									Page 1 of 3		

NATIONAL HEALTH MANAGEMENT INFORMATION SYSTEM HEALTH FACILITY MONTHLY SUMMARY FORM

VERSION 2019

State & LGA officers

- Complete the document as per local existing protocols, indicating **only** the number of pregnant women who received Iron and Folic Acid.
- In row 31 'Hematinics (Iron and Folic Acid Supplements)'

State & LGA officers

Module 7. Monitoring and reporting Monitoring Forms to be Completed (cont'd)



Date:	B/P	Weigh Next App				_	
					PRIMARY ASSESSMENT		The second
		CLIP LETTER SUMMARISES HERE		7		DATE:	
					HISTORY OF PRESENT PREGNANCY		
	2012 20 -			1	DISCHARGE		
				4			
				-	URINARY SYMPTOMS		
		GLUE REPORTS OF INVESTIGATION HERE			OF ANKLES		
				-	OTHER SYMPTOMS		
		1		_	PHYSICAL EXAMINATION		HEIGHT
		2			GENERAL CONDITION	OEDEMA	WEIGHT
		3				ANAEMIA	8.P .
				-	RESPIRATORY SYSTEM		URINE
		4					BREAST &
		5			CARDIOVASCULAR SYSTEM		4
•					ABDOMEN	SPLEEN CM	- 45
		6	and the second se	-		LIVER CM	GENOTYF
	-	7					KAHN
100000000000000000000000000000000000000		8					GROUPE
			1000		VAGINAL EXAMINATION		CHEST
		TD VACCINE		1	OTHER ABNORMALITIES		CHEST
		DATE GIVEN	DATE Next Appointment		OTHER ABNORMALITIES	+	-
		· TT 1			in the second se		EXAMINER
		TT 2		complete t	t/ .		SIGNATURE
	1000	TT 3 TT 4		consulta	at		
		TT 5		- Vi			
		LG		- 17	SPECIAL INSTRUCTION REGARDING PDERFERION	#	- 14
		DRUGS GIVEN			1 · · · · · · · · · · · · · · · · · · ·		
					and the second s		
		IRON FOLATE	The second second second	-			

- Complete as per local existing protocols, except for pregnant women who are receiving MMS.
- For MMS:

Remember to also write down the approximate date of when she will be receiving her 2nd MMS bottle.

State & LGA officers



 \mathcal{C}

Hea	ilth I	acili	ty in	forma	ation					1. Mon	th / Year: M M / Y	Y Y Y 2. H	ealth Facility	Code (Numbe	er):		
3. H	ealt	h Fac	cility	Nam	ie:		4.	evel of Care: Pr	imary 🗌 Sec	ondary Tertiary 5. LGA Nam	ie:		6. Ward Na	me:			
. C	omn	nunit	y Na	me:			8.	Health Worker Name	c		9. Health Worker I	Designation:	Nurse 🗌 M	idwife 🗌 C	HEW JCH	EW 🗌 Othe	r:
Preg	inan	t Wo	men	s Rec	ord												
/N	Dat	e			ANC card number	Pregnant Woman name	is 4	Phone number		łome iddress	Husband's name	ANC visi number	t Pregnancy week	Anaemia	IFAS given today?	MMS given today?	If yes,
	D	D	М	М										Yes	Yes	Yes	- 14 bi
	D	D	м	М										Unknown Yes No	Yes	Yes	- 1º bi
														Unknown Yes	Yes	Ves	- 1º 6
	D	D	М	М										No Unknown		No	2 2 2
	D	D	М	М										Yes No Unknown	Yes	Yes	1 ^{µ+} b 2 [™] b
	D	D	М	М										Yes	Yes	Ves	1 1 b 2 c 1
_	D	D	м	М										Unknown Yes No	Yes	Yes	- 1+ b 2* 1
														Unknown Yes	Yes	Ves	- 🗌 1º b
	D	D	M	M										No Unknown Yes	Ves	Ves	2 [∞] t
	D	D	М	М										No Unknown	No No	No No	210
	D	D	М	М										Yes No Unknown	Yes	Yes	1≓ b 2 [∞] l
	D	D	М	М										Yes	Yes	Yes	- 1= b 2= 1
		D												Unknown Yes No	Yes	Yes	- 1 1 ^µ b 2 [∞] 1
		U	IVI	191										Unknown	Yes	Yes	- 2~ t
	D	D	М	М										No Unknown	No	No No	2** 1
	D	D	М	М										Ves No Unknown	Yes	Yes	- 1+ b 2* t
		fotal	5														
_	natu ne o		ility-		harge:					Abbreviations: ANC: antenatal care; IFAS: iron and folic acid s	unnlomontation		s	\$ 2		RITION	-

Carbon copies:

- Health facility: pink copy
- LGA level: yellow copy
- Nutrition International: original copy



Role play

Practice using the monitoring forms.

Scenario:

It is the 1st ANC Module upon receipt of MMS in Dass town PHC, kindly demonstrate:

- a) How will the MMS be released from the pharmacy?
- b) How will the ANC card, daily register, and Form 1 be filled by the Maternity-in-Charge?





* RIRF: Requisition, Issue, and Report Form



Contact Nutrition International for Resources & Guidance

RIRF

BIM	ONTHLY REQUISITION, IS	SUE, AND REF	PORT FO	RM – SEI	RVICE DI	LIVERY	POINTS						
Repo	orting Period - Starting Month:	·					Reporting	g Period - E	nding Mo	nth:			Year:
SDP/	'Health Facility Name:						LGA Nam	e:					State: Bauchi
	Columns	A	В	С	D	E	F	G	н	1	J	к	L
			Stock balance at the beginning of the 2	Quantities received during the last 2 months	Cons over the past 2 months	Losses	Adjustments	Stock on Hand	Physical Count	АМС	Max Quantity	Order Quantity	-
N°	Product Description	Unit	months					(B+C)-(D+E+F)		Δ+2	I×4	J-H	Remark
1	Multiple Micronutrient Supplement (MMS)	Bottle (100 Tablets)											
2													
3													
4													
5													
6													
7													
8													
9													
10													
11													
12													
	TOTAL												
	and hour	RE	QUISITION			Date:			Prepared by		R	SSUE	
repar	red by:					Date:			Prepared by Supplied by				
uthor	rized by					Date:			Received b				

Complete the document as per local existing protocols for public health commodities, with some modifications:

- Columns "B to L" should be filled in line with standard/existing protocols.
- In the column entitled "product description", MMS should be captured.
- In the column entitled "units", "bottle (100 tablets)" should be captured.



 \mathcal{C}

2

Form 2

1. Month / Year: 🔟 🔟 / 😤 😤 🖉 2. H	ealth Facility Code (Number):	3	Health Facility Name:	
4. Level of Care: Primary Secondary Tertia	ry 5. State Name:		6. LGA Name:	
7. Ward Name:		8. Community Nat	ne:	
9. Health Worker Name:				
10. Health Worker Designation: Pharmacy-in-ch	arge Pharmacy-techni	cian Other*		
		*For health post	s, Form 2 can be complete	d by the maternity-in-ch
Stock Record				
A. Opening stock of MMS bottles this month (n	umber):			A
B. MMS bottles received this month (number):				В
C. Total quantity of MMS bottles in stock (num	ber):			A + B
D. MMS bottles distributed this month (number	r):			D
Comments:				1
Abbreviation: MMS: multiple micronutrient sup	oplementation			
Signature				
1. Name of facility-in-charge:				
3. Date of signature: 0 0 - M U - Y	Y Y Y		2. Signature o	f facility-in-charge

Carbon copies:

- Health facility: pink copy
- LGA level: yellow copy
- Nutrition International: original copy

Role play

Practice using the monitoring forms.

Scenario: 40 bottles of MMS were sent to Doguwa PHCC in Giade LGA on October 5th, 2023.

Demonstrate the following:

- (a) How were the MMS bottles received by the Facility-in-Charge?
- (b) How will Form 2 be filled out by the Pharmacy-in-Charge / Maternity-in-Charge / Facility-in-Charge on October 30th, 2023?
- (c) How will the bimonthly RIRF form be filled by the Pharmacy-in-Charge and Facility-in-Charge by November 29th, 2023?



Contact Nutrition International for Resources & Guidance

Overview of MMS Standard Package Training

- Module 1. Setting the Tone
- Module 2. Nutrition During Pregnancy
- Module 3. From IFAS to MMS
- Module 4. Key Messages on the Provision of MMS
- Module 5. MMS Factsheet
- Module 6. Standard Operating Procedures (SOPs)
- Module 7. Monitoring and Reporting
- Module 8. Closing of the training



Module 8. Closing of the training Cascade Planning

- Training plan
- Team of trainers
- Trainer's manual and agenda
- Focal personnel



- The post-test evaluation form will help assess how much you learned from this training.
- The training evaluation form will allow you to provide your feedback on this training.



Module 8. Closing of the training

✓ Post-test assessment

✓ Training evaluation

 \checkmark Comments from the team



Contact Nutrition International for Resources & Guidance